BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Creative Planning

Creative Planning lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 49,347 shares of the biotechnology company’s stock after acquiring an additional 2,734 shares during the quarter. Creative Planning’s holdings in BioCryst Pharmaceuticals were worth $375,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in BCRX. Deerfield Management Company L.P. Series C lifted its holdings in BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock worth $50,279,000 after buying an additional 3,140,804 shares in the last quarter. Kynam Capital Management LP lifted its holdings in BioCryst Pharmaceuticals by 41.9% during the 1st quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock worth $33,160,000 after buying an additional 1,927,491 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in BioCryst Pharmaceuticals by 528.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 1,112,232 shares of the biotechnology company’s stock worth $6,874,000 after buying an additional 935,132 shares in the last quarter. Point72 Europe London LLP acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $1,654,000. Finally, TD Asset Management Inc acquired a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth approximately $1,487,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $7.67 on Friday. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The stock has a market capitalization of $1.59 billion, a PE ratio of -12.57 and a beta of 1.89. The company has a fifty day moving average of $7.78 and a 200-day moving average of $6.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.19) EPS. Equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.